2024 Annual Meeting: Industry Product Sessions
See what’s new with industry during these educational and product-oriented sessions taking place during the 2024 Annual Meeting. These unique sessions provide exhibiting companies the opportunity to present new research findings on products, detail products, conduct demonstrations, and highlight new products.
These sessions are solely promotional and are not eligible for CME credit.
Session schedule
Friday, March 8, 2024 | Theater 1 | Booth 3347
10:30 a.m. - 11:15 a.m.
Treatment update: The First FDA-Approved Treatment for Molluscum Contagiosum
12:00 p.m. - 12:45 p.m.
See what's possible with Olumiant: 3-year data
This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and live Q&A following the presentation.
1:30 p.m. - 2:15 p.m.
A Peer Perspective on an Oral Treatment Option for Adults with Moderate-to-Severe Plaque Psoriasis
This program describes the efficacy and safety profile of an oral product. You will learn more about the pivotal clinical trials, product function, and patient support services.
Friday, March 8, 2024 | Theater 2 | Booth 2947
11:15 a.m. - 12:00 p.m.
Comorbidities in Psoriasis from Psoriatic Arthritis to Obesity
Join a panel of psoriasis experts for a discussion on important clinical considerations for comorbid conditions of psoriasis.
12:45 p.m. - 1:30 p.m.
Understanding Atopic Dermatitis of the Hand and Foot
Saturday, March 9, 2024 | Theater 1 | Booth 3347
10:30 a.m. - 11:15 a.m.
Insights into Adbry® and a Patient Spotlight: An Update on the Efficacy and Safety of the Only Biologic Targeting IL-13 for Moderate-to-Severe Atopic Dermatitis
A patient-focused program where two leading dermatologists review the latest efficacy and safety data of Adbry® and feature a real-world patient to discuss insights into their treatment experience.
12:00 p.m. - 12:45 p.m.
A Treatment Option for Patients With Uncontrolled Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
1:30 p.m. - 2:15 p.m.
A New Approach to Skin Barrier Health
RoC has developed a new approach to skin barrier health. SVP of Research & Development, Art Pellegrino, and board-certified Dermatologist, Dr. Muneeb Shah, will present the technology behind this innovation.
Saturday, March 9, 2024 | Theater 2 | Booth 2947
11:15 a.m. - 12:00 p.m.
From Heterogeneity Comes New Insights: Exploring the Role of T Cells and OX40 in Atopic Dermatitis
OX40 signaling can play a critical role in AD pathogenesis by driving T-cell-mediated effector and memory responses that orchestrate inflammation and disease chronicity.
Sunday, March 10, 2024 | Theater 1 | Booth 3347
12:00 p.m. - 12:45 p.m.
Unlocking Skin's Potential
